HRMY
Harmony Biosciences Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$42.25
+0.93%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
10.5x
EV/EBITDA
7.0x
Market Cap
$2.46B
MomentumView details →
1D Return
+0.93%
YTD Return
+12.43%
RSI (14)
65.0
ValuationView details →
P/E (Fwd)
10.5x
EV/EBITDA
7.0x
Market Cap
$2.46B
RSI (14)
65.0
MomentumView details →
1D Return
+0.93%
YTD Return
+12.43%
SummaryUpdated Jun 1, 2026
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company founded in 2017 and based in Plymouth Meeting, Pennsylvania. The company went public in August 2020 and has established itself as a profitable biotechnology firm focused exclusively on developing and commercializing therapies for patients with rare neurological disorders. Since its founding, Harmony has built a robust pipeline of eight assets across three distinct therapeutic franchises, with its flagship product WAKIX generating over $2 billion in cumulative sales since launch.
Similar companies
Latest newsMore news →
Aurora Investment Counsel acquired a new position in Harmony Biosciences Holdings, Inc., purchasing 65,148 shares valued at approximately $2.37 million, as disclosed in a recent SEC filing.16d agoHarmony Biosciences highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.21d agoHarmony Biosciences announced initial Phase 1 clinical data for its orexin-2 agonist BP-205, showing favorable pharmacokinetic and safety profiles, and plans to initiate Phase 1b and Phase 2 trials in 2026 and 2027.31d ago